

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
March 15, 2024

**DRAFT MEETING ROSTER**

---

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Joyce Frimpong, PharmD**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Ranjana H. Advani, MD**

Saul A. Rosenberg Professor of Lymphoma  
Division of Oncology  
Stanford University School of Medicine  
Stanford, California

**William J. Gradishar, MD**

Professor of Medicine/Betsy Bramsen Professor of  
Breast Oncology  
Chief, Hematology/Oncology  
Robert H. Lurie Comprehensive Cancer Center  
Feinberg School of Medicine at Northwestern  
University  
Chicago, Illinois

**Christopher H. Lieu, MD**

Associate Professor of Medicine  
Associate Director for Clinical Research  
Director, Gastrointestinal Medical Oncology Program  
University of Colorado  
Aurora, Colorado

**Ravi A. Madan, MD**

*(Chairperson)*  
Senior Clinician  
Head, Prostate Cancer Clinical Research Section  
Genitourinary Malignancies Branch  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Jorge J. Nieva, MD**

Associate Professor of Clinical Medicine  
Section Head, Solid Tumors  
University of Southern California (USC)  
Norris Comprehensive Cancer Center  
Keck School of Medicine of USC  
Los Angeles, California

**Daniel Spratt, MD**

Vincent K Smith Chair, Department of Radiation  
Oncology  
Professor of Radiation Oncology and Urology  
University Hospitals Seidman Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Neil Vasan, MD, PhD**

Assistant Professor  
Division of Hematology & Oncology  
Department of Medicine  
Herbert Irving Comprehensive Cancer Center  
Columbia University Medical Center  
New York, New York

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
March 15, 2024

**DRAFT MEETING ROSTER (cont.)**

---

---

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)**

**Tara Frenkl, MD, MPH**

Senior Vice President, Head of Oncology Development  
Bayer Pharmaceuticals  
Whippany, New Jersey

**TEMPORARY MEMBERS (Voting)**

**John Deflice, MD**

*(Patient Representative)*  
Albuquerque, New Mexico

**Sally Hunsberger, PhD**

Mathematical Statistician  
Biostatistics Research Branch  
National Institute of Allergy and Infectious Diseases  
NIH  
Bethesda, Maryland

**Mary Kwok, MD**

Clinical Associate Professor  
Division of Hematology-Oncology  
University of Washington  
Seattle, Washington

**Susan Lattimore, RN, GCPH**

Assistant Professor, Pediatrics  
Associate Director – The Hemostasis & Thrombosis  
Center  
Oregon Health & Science University  
Portland, Oregon

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
March 15, 2024

**DRAFT MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

*(Afternoon session only)*  
Director, Oncology Center of Excellence (OCE)  
Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Marc Theoret, MD**

Deputy Center Director, OCE  
Supervisory Associate Director (Acting)  
OOD, OND, CDER, FDA

**Nicole Verdun, MD**

Super Office Director  
Office of Therapeutic Products (OTP)  
Center for Biologics Evaluation and Research (CBER)  
FDA

**Bindu Kanapuru, MD**

Clinical Team Leader  
Division of Hematologic Malignancies II (DHMII)  
OOD, OND, CDER, FDA

**Robert Sokolic, MD**

Branch Chief  
Malignant Hematology Branch (MHB)  
Division of Clinical Evaluation Hematology (DCEH)  
Office of Clinical Evaluation (OCE)  
OTP, CBER, FDA

**Helkha Peredo-Pinto, MD, MPH**

Clinical Reviewer  
MHB, DCEH, OCE, OTP, CBER, FDA

**Cong Wang, PhD**

Statistical Reviewer  
Therapeutics Evaluation Branch 1 (TEB1)  
Division of Biostatistics (DB)  
Office of Biostatistics and Pharmacovigilance  
(OBPV), CBER, FDA

**Poornima Sharma, MD**

Clinical Reviewer  
MHB, DCEH, OCE, OTP, CBER, FDA

**Xue (Mary) Lin, PhD**

Statistical Reviewer  
TEB1, DB, OBPV, CBER, FDA